Journal ArticleDOI
Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study
TLDR
A 2-year phase III trial designated ANCHOR as discussed by the authors compared ranibizumab with verteporfin photodynamic therapy (PDT) in treating predominantly classic CNV.About:
This article is published in Ophthalmology.The article was published on 2009-01-01. It has received 1259 citations till now. The article focuses on the topics: Ranibizumab & Verteporfin.read more
Citations
More filters
Journal ArticleDOI
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Geeta A. Lalwani,Philip J. Rosenfeld,Anne E. Fung,Sander R. Dubovy,Stephen Michels,William J. Feuer,Janet L. Davis,Harry W. Flynn,Maria Esquiabro +8 more
TL;DR: The PrONTO Study using an OCT-guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravItreal injections were required.
Journal ArticleDOI
Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP).
TL;DR: Assessing long-term outcomes 7 to 8 years after initiation of intensive ranibizumab therapy in exudative age-related macular degeneration patients found one third of patients demonstrated good visual outcomes, whereas another third had poor outcomes.
Journal ArticleDOI
Ten years of anti-vascular endothelial growth factor therapy
TL;DR: The discovery of V EGFA, the successes and challenges in the development of VEGFA inhibitors and the impact of these agents on the treatment of cancers and ophthalmic diseases are discussed.
Journal ArticleDOI
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Usha Chakravarthy,Simon P. Harding,Chris A Rogers,Susan M. Downes,Andrew J. Lotery,Lucy Culliford,Barnaby C Reeves +6 more
TL;DR: The findings in the Inhibition of VEGF in Age-related choroidal Neovascularisation trial highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought.
Journal ArticleDOI
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
David M. Brown,Peter A. Campochiaro,Robert B. Bhisitkul,Allen C. Ho,Sarah Gray,Namrata Saroj,Anthony P. Adamis,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of ranibizumab provide an effective treatment for macular edema after central retinal vein occlusion, with low rates of ocular and nonocular safety events.
References
More filters
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal Article
Collaborative overview of randomized trials of antiplatelet therapy .1. prevention of death, myocardial-infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
R Altman,L Carreras,R Diaz,E Figueroa,E Paolasso,J C Parodi,J F Cade,G Donnan,M J Eadie,T P Gavaghan,E F Osullivan,D Parkin,Renny Jtg.,C Silagy,H Vinazzer,F Zekert,H Adriaensen,J M Bertrandhardy,M Bran,J L David,J Dricot,E Lavennepardonge,R Limet,A Lowenthal,M Moriau,S Schapira,P Smets,J Symoens,R Verhaeghe,Marc Verstraete,A Atallah,H Barnett,R Batista,J Blakely,J A Cairns,R Cote,J Crouch,G Evans,J M Findlay,M Gent,Y Langlois,J Leclerc,J Norris,G F Pineo,P J Powers,R Roberts,L Schwartz,J Sicurella,W Taylor,P Theroux,Alexander G.G. Turpie,R D Weisel,J Cui,L Liu,J Pirk,C Bay,G Boysen,J B Knudsen,P Petersen,P S Sorensen,H K Tonnesen,P T Harjola,J C Arcan,B Balkau,J Blanchard,J P Boissel,B Boneu,M G Bousser,M Brochier,M Cloarec,G Cribier,M Dechavanne,P Drouin,E Eschwege,B Guiraudchaumeil,R Hugonot,A Leizorovicz,Y Loria,L Michat,J Mirouze,E Panak,J Pasteyer,A Rascol,L Revol,Maarten Van Roy,J Selles,G Slama,C Starkman,M Teule,N Thibult,M Verry,F W Albert,K Andrassy,K Breddin,R Eckel,A Encke,J Frohlich,B Hartung,H W Heiss,H Hess,B Hofling,D Krause,G Latta,H Linke,D Loew,R Lorenz,K Middleton,G Novak,M Oldendorf,N Pfluger,D Raithel,R Reuter,G Schettler,J Schnitker,W Schoop,H Stiegler,K Uberla,G Vogel,M Weber,I Welbers,E Zeitler,G Arapakis,T Chan,C K Mok,R Szabo,N P Misra,K Reddy,G A Fitzgerald,A Apollonio,F Balsano,A Basellini,L Candelise,Mariella Catalano,N Ciavarella,G Ciuffetti,S Coccheri,M Cortellaro,G Corvi,V Coto,Giovanni Davì,R Decaterina,T Diperri,C Fieschi,R Gentile,L Gregoratti,Paolo Gresele,M Lavezzari,A Libretti,B Magnani,G.G. Nenci,G Pagano,Carlo Patrono,L Pedrini,M Pini,Paolo Prandoni,F Romeo,F Rovelli,G Rudelli,G Ruvolo,G P Signorini,G Tognoni,Francesco Violi,T Fujimori,M Kageyama,T Katsumura,S Kitamura,K Maeda,A Suzuki,H Tohgi,S Uchiyama,H Utsumi,A M Garcia,A Algra,Denottolander Gjh.,Kupper Ajf.,J Vangijn,H Hart,L J Kappelle,P J Koudstaal,T Lemmens,J Lodder,M Pannebakker,P W Serruys,A Vandenbelt,J Vandermeer,A B Vandervijgh,Verheugt Fwa.,G Veth,J Dale,K A Johannessen,E Thaulow,P Popescu,N Tiberiu,Aznar Jrd.,E Esmatjes,P Guiteras,J Lasierra,P Lopeztrigo,A Oriol,L Pomar,E Rocha,F D Sanchez,J Sanchorieger,G Sanz,Berglund Ulf.,C Blomstrand,M Boberg,M Britton,C E Elwin,C Helmers,J Holm,L Janzon,S Juulmoller,H Mulec,J E Olsson,S Persson,G Rasmanis,A Rosen,K Samuelsson,J Soreff,N Wahlgren,L Wallentin,H R Baur,M Bokslag,A Bollinger,B Meier,M Pfisterer,C Sitthiamorn,E J Acheson,P Appleby,A W Asscher,A Aukland,Colin Baigent,S Bala,A H Barnett,P Bell,S Bews,Born Gvr.,J P Branagan,N Brooks,M J Brown,N L Browse,R Capildeo,M Carmalt,A E Carter,I Chalmers,Mike Clarke,Robert Clarke,Clyne Cac.,Rory Collins,Cooke,G Coutts,D H Cove,P S Crowther,W F Cuthbertson,D Debono,C Dickerson,J P Dickinson,Richard Doll,J A Dormandy,D Dunbabin,S Ell,P Elphinstone,P Elwood,V Englishby,B Farrell,C Fiskerstrand,M Flather,T Foley,T Foulds,K M Fox,Peter Franks,H Fraser,T Gardecki,M Gawel,A E Gent,A H Gershlick,J Godwin,M Goldman,C Gray,D Gray,Richard Gray,H Handoll,G Hankey,Harrison Mjg.,N Henderson,S Heptinstall,S F Hobbiger,E W Jones,Jones Nag.,S Jost,D Julian,J Kellett,R C Kester,G Lowe,J Mackenzie,C N McCollum,G Mead,T W Meade,D Mendelow,J C Miller,G K Morris,C Nichol,M Noble,Obrien,M Ogier,Sarah Parish,M J Parry,Richard Peto,Janet T. Powell,P Pozzilli,N Qizilbash,A Rahman,S M Rajah,D H Richards,S Richards,Ruth M. Ripley,V C Roberts,F C Rose,Russell Rwr.,P C Rubin,C V Ruckley,Peter Sandercock,Shaw Mdm.,K M Shaw,J H Shelley,J Slattery,Peter Sleight,S J Smith,P Stewartlong,P M Sweetnam,Tansey Mjb.,H Tindall,J Turney,H M Tyler,N C Varey,M P Vessey,M G Walker,M A Walker,C P Warlow,R G Wilcox,H Willems,E H Wood,E Wynjones,H P Adams,B Barton,R F Bedford,B L Bick,S Bingham,B G Brown,T Bryant,J Buring,C F Cabot,P Canner,J Chesebro,O D Chrisman,G P Clagett,J A Colwell,M Dyken,D Ellis,W S Fields,C Furberg,V Fuster,S Goldman,J Granett,R M Green,D Green,R Hardy,L A Harker,W H Harris,R G Hart,W K Hass,Charles H. Hennekens,D Hill,M Hume,M C Igloe,G Johnson,S Jonas,G Knatterud,T R Kohler,N J Lembo,D Lewis,E Lockhart,P Majerus,Mcenany,R Mckenna,J L Mehta,J S Meyer,B Molony,T Moritz,D M Nicoloff,G Nycz,H Ono,G A Pantely,S J Phillips,Paul M. Ridker,J T Robertson,R Rothbart,E W Salzman,R D Sautter,R C Schlant,J A Schoenberger,M V Sengekontacket,G Sharma,P Steele,K P Steinnagel,J Stratton,J M Sullivan,G Timmis,J F Toole,Walker,S Weisman,C W White,M Wirecki,D Wombolt,R Wong,Salim Yusuf,K Zadina,D Zucker +418 more
TL;DR: There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
Journal ArticleDOI
Some Methods for Strengthening the Common χ 2 Tests
TL;DR: In this article, the authors discuss two kinds of failure to make the best use of x2 tests which I have observed from time to time in reading reports of biological research, and propose a number of methods for strengthening or supplementing the most common uses of the ordinary x2 test.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2.
TL;DR: To report 24-month vision and fluorescein angiographic outcomes from trials evaluating photodynamic therapy with verteporfin (Visudyne) in patients with subfoveal choroidal neovascularization caused by age-related macular degeneration (AMD).
Related Papers (5)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Jeffrey S. Heier,David M. Brown,Victor Chong,Jean-François Korobelnik,Peter K. Kaiser,Quan Dong Nguyen,Bernd Kirchhof,Allen C. Ho,Yuichiro Ogura,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Yuhwen Soo,Majid Anderesi,Georg Groetzbach,Bernd Sommerauer,Rupert Sandbrink,Rupert Sandbrink,Christian Simader,Ursula Schmidt-Erfurth +20 more